EXFORGE HCT 10-320-25 MG TAB

What it is

EXFORGE HCT 10-320-25 MG TAB is how the CMS NADAC file names this product. The FDA NDC Directory lists it as amlodipine valsartan and hydrochlorothiazide, under the trade name “Exforge HCT”.

FDA gives its dosage form as tablet, film coated and its route as oral.

The labeler, the company named on the label, is Novartis Pharmaceuticals Corporation.

FDA lists it under 4 Established Pharmacologic Classes: Angiotensin 2 Receptor Blocker, Calcium Channel Blocker, Dihydropyridine Calcium Channel Blocker and Thiazide Diuretic.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00078-0563-15.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $463.43 for 30 tablets (30 × $15.44773 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-01-07. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 4, carried forward from the previous file.

This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-01-07. The file is new; the price is not.

NADAC also lists, on the row of one brand NDC, what pharmacies pay for the generic equivalent, a different product: $5.44347 per EA filed.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What NADAC measures · Why 30 tablets · NADAC explanation codes · Carried-forward prices

The NDC

• 00078-0563-15 · Novartis Pharmaceuticals Corporation · $15.44773 per EA · eff. 2026-01-07 filed carried forward

Compared with its class

Its NADAC price is $15.44773 per EA filed.

Of the 107 other products in FDA’s Angiotensin 2 Receptor Blocker class priced per EA, 7 have a higher middle NADAC price and 100 a lower one. The one in the middle is CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB, at $1.07781 per EA filed (eff. 2026-09-23).

Of the 107 other products in FDA’s Calcium Channel Blocker class priced per EA, 4 have a higher middle NADAC price and 103 a lower one. The one in the middle is OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-5-25 MG, at $0.99481 per EA filed (eff. 2026-09-23).

Of the 67 other products in FDA’s Dihydropyridine Calcium Channel Blocker class priced per EA, 4 have a higher middle NADAC price and 63 a lower one. The one in the middle is NICARDIPINE 20 MG CAPSULE, at $1.12012 per EA filed (eff. 2026-09-23).

Of the 68 other products in FDA’s Thiazide Diuretic class priced per EA, 4 have a higher middle NADAC price and 64 a lower one. The one in the middle is TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB, at $0.3567 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-07, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part D paid $364.68 for 30 tablets, at an average of $12.15584 per EA in 2024 (2024-01-01 to 2024-12-31) for “Exforge HCT” and “Amlodipine/Valsartan/HCThiazid”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 993 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.